patient-reported outcomes measurement information system cognitive function short scale (ProMIS Neurosciences)
90
Structured Review
ProMIS Neurosciences
patient-reported outcomes measurement information system cognitive function short scale
Patient Reported Outcomes Measurement Information System Cognitive Function Short Scale, supplied by ProMIS Neurosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patient-reported+outcomes+measurement+information+system+%E2%80%93+cognitive+function+%E2%80%93+short/6+item+patient+reported+outcomes+measurement+information+system+cognitive+function+and+abilities+scales/pmc10973071-92-11-10
Average 90 stars, based on 1 article reviews
Patient Reported Outcomes Measurement Information System Cognitive Function Short Scale, supplied by ProMIS Neurosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patient-reported+outcomes+measurement+information+system+%E2%80%93+cognitive+function+%E2%80%93+short/6+item+patient+reported+outcomes+measurement+information+system+cognitive+function+and+abilities+scales/pmc10973071-92-11-10
Average 90 stars, based on 1 article reviews
patient-reported outcomes measurement information system cognitive function short scale - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Functional Assay:Article Title: Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer Article Snippet: .. Study Instruments and Time Points Instrument/Measure: Screening Baseline (4- week window from consent) 12-weeks post-baseline (+/- 2-week window) *24-weeks post-baseline (+/- 2-week window) Electronic health record review X Adapted NCCN Distress Thermometer X Medication Event Monitoring System (MEMS Caps) To be used throughout the 24-week study period Demographics X Medication Adherence Report Scale (MARS-5) X X X Breast Cancer Prevention Trial Symptom Checklist (BCPT) X X X Cancer Therapy Satisfaction Questionnaire (CTSQ) X X X Hospital Anxiety and Depression Scale (HADS) X X X Functional Assessment of Cancer Therapy (FACT-B) X X X Measure of Current Status (MOCS) X X X Beliefs About Medications Questionnaire – Adjuvant Endocrine Therapy (BMQAET) X X X Multidimensional Scale of Perceived Social Support (MSPSS) X X X Self-Efficacy in Appropriate Medication Use Scale (SEAMS) X X X Self-Efficacy For Managing Symptoms and Taking AET Questionnaire (SelfEfficacy For Symptoms) X X X Patient-Reported Medications:Article Title: Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer Article Snippet: .. Study Instruments and Time Points Instrument/Measure: Screening Baseline (4- week window from consent) 12-weeks post-baseline (+/- 2-week window) *24-weeks post-baseline (+/- 2-week window) Electronic health record review X Adapted NCCN Distress Thermometer X Medication Event Monitoring System (MEMS Caps) To be used throughout the 24-week study period Demographics X Medication Adherence Report Scale (MARS-5) X X X Breast Cancer Prevention Trial Symptom Checklist (BCPT) X X X Cancer Therapy Satisfaction Questionnaire (CTSQ) X X X Hospital Anxiety and Depression Scale (HADS) X X X Functional Assessment of Cancer Therapy (FACT-B) X X X Measure of Current Status (MOCS) X X X Beliefs About Medications Questionnaire – Adjuvant Endocrine Therapy (BMQAET) X X X Multidimensional Scale of Perceived Social Support (MSPSS) X X X Self-Efficacy in Appropriate Medication Use Scale (SEAMS) X X X Self-Efficacy For Managing Symptoms and Taking AET Questionnaire (SelfEfficacy For Symptoms) X X X Patient-Reported Adjuvant:Article Title: Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer Article Snippet: .. Study Instruments and Time Points Instrument/Measure: Screening Baseline (4- week window from consent) 12-weeks post-baseline (+/- 2-week window) *24-weeks post-baseline (+/- 2-week window) Electronic health record review X Adapted NCCN Distress Thermometer X Medication Event Monitoring System (MEMS Caps) To be used throughout the 24-week study period Demographics X Medication Adherence Report Scale (MARS-5) X X X Breast Cancer Prevention Trial Symptom Checklist (BCPT) X X X Cancer Therapy Satisfaction Questionnaire (CTSQ) X X X Hospital Anxiety and Depression Scale (HADS) X X X Functional Assessment of Cancer Therapy (FACT-B) X X X Measure of Current Status (MOCS) X X X Beliefs About Medications Questionnaire – Adjuvant Endocrine Therapy (BMQAET) X X X Multidimensional Scale of Perceived Social Support (MSPSS) X X X Self-Efficacy in Appropriate Medication Use Scale (SEAMS) X X X Self-Efficacy For Managing Symptoms and Taking AET Questionnaire (SelfEfficacy For Symptoms) X X X Patient-Reported |
